TVCMALL
12.3.2023 08:16:39 CET | Business Wire | Pressemeddelelse
Nylig blev Mobile World Congress (MWC) 2023 afholdt i Barcelona, og det var en stor succes. Mere end 88 000 deltagere og 2400+ udstillere deltog i denne begivenhed, herunder mange leverandører af mobiltelefontilbehør og grossister. Som Europas førende one-stop-shop for mobiltilbehør og engros/integreret forsyningskædeserviceplatform, TVCMALL deltaget også i dette digitale/mobile arrangement. TVCMALL, der er baseret i Shenzhen, Kina, som er verdens elektroniske center, tilbyder kunder en B2B mobiltilbehør engros-, sourcing- og tilpasningsløsning. Forskellige klassiske mobiltelefoncovers med læderfinish, opladere med multifunktioner og Amorus bærbare karaokehøjtalere fra TVCMALL fik stor ros af de fremmødte.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20230307005694/da/
TVCMALL brings one-stop wholesale solution to MWC 2023 (Photo: Business Wire)
MWC er en af verdens vigtigste telekommunikations- og teknologimesser. I løbet af de sidste 4 dage er aspekter som den seneste trend inden for mobilteknologi inklusive intelligent udstyr, 5G-netværk, AI og digitalisering blevet introduceret og delt med resten af verden.
Under showet mødte TVCMALL mange gamle kunder og mange nye venner. Mange af dem er som følger:
- Top forhandlere og distributører af mobiltelefontilbehør online
- B2C platform sælgere, Dropshippere
- Fysiske butikker, supermarkedssælgere, teleselskaber
- Gave-Tilpasningskunder (især for myndigheder, virksomheder, skoler og andre offentlige ydelser)
- OEM & ODM & OBM kunder
- Detail & Mobiltelefon værksteder
Mange kunder har samarbejdet med TVCMALL i over ti år siden etableringen i 2008, og de er vokset og udviklet sig hurtigt med TVCMALL. De udtrykte deres store påskønnelse og store taknemmelighed til TVCMALL for at levere en one-stop shop til engros, sourcing, tilpassede tjenester og andre forsyningskædetjenester.
Hvorfor de vælger TVCMALL som énuundgåelig og vigtig langsigtet partner? Fordi TVCMALL tilbyder et komplet produktkatalog med mere end 600.000 SKU'er online, og hver uge opdateres 6.000 nye produkter. Engros-processen, marketingsupport og kundeservice er effektive. TVCMALL har gode intentioner om at vokse sammen med sine kunder.
TVCMALLs omfattende anskaffelsesomkostninger er relativt lave, servicekonsistens og stabilitet er meget stærk. Derfor foretrækker mange kunder one-stop-tjenesteudbydere som TVCMALL.
Under MWC har TVCMALL etableretgod kontakt med nogle fremragende produktleverandører og e-handelstjenesteudbydere (af mobile, 3C elektroniske enheder og tilbehør).
Ii den nærmeste fremtid, med kontinuerlig TVCMALL brand og platform opgradering, vil TVCMALL styrke sit mål, "At hjælpe iværksættere med at realisere deres drømme om at lancere og opretholde en succesfuld detailforretning", og vil overholde sin forretningsdriftsfilosofi "Together we thrive". Med hensyn til specifikke strategier vil TVCMALL følge de 4 følgende anvisninger:
- Platform branding —Betjen TVCMALL-platformen som et fremtidigt århundrede gammelt brand
- Produktisering af tjenesterne - alle tjenester fra TVCMALL sammen med ideen om produktisering.
- ProduktDyb pløjning — For at være den bedste skal du trives.
- Lokalisering af TVCMALL-tjenesten — Gå globalt og lokalisere: Start lokalt marketing- og serviceteam, dybdegående forståelse og effektiv service.
TVCMALL vil se dig igen i Barcelona 2024!
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20230307005694/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum